Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658057 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL8814526 | 0.91 | CYP1A2 (0.50) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL10163498 | 0.91 | CYP1A2 (0.46) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL899391 | 0.85 | CYP1A2 (0.36) | CYP1A2CYP2D6 | |
| SCHEMBL13479762 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL28252848 | 0.79 | CYP1A2 (0.35) | CYP1A2CYP2D6 | |
| SCHEMBL9910700 | 0.77 | CYP1A2 (0.35) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL15490090 | 0.77 | CYP1A2 (0.35) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL22766036 | 0.77 | CYP1A2 (0.32) | CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL9637783 | 0.77 | CA1 (0.45) | CYP1A2CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192575-A1 | TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME | SK CHEMICALS CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| CN-1094034-A | 25 carboxylic acid derivative of vitamin D series, its method for making and intermediate product, contain the medicine of this derivative and medicinal | SCHERING AG (DE) | 1994-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192575-A1 | TRICYCLODECANE DIMETHANOL COMPOSITION AND PREPARATION METHOD OF THE SAME | DHCR7, DHCR24, CYP19A1 | CYP1A2 41/4885CYP2D6 326/4885ALDH1A1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.